New late-breaking findings from the phase 3b ORATORIO-HAND trial (NCT04035005) of ocrelizumab (Ocrevus; Genentech) showed that the treatment significantly delayed overall disability progression and worsening of upper limb function in patients with pr... [3290 chars].. reed more
